PBM and NS have consulted for and or received lecture fees on SGLT2 inhibition from Napp (PBM), Merck Sharp & Dohme (NS), AstraZeneca (PBM, NS), and Boehringer Ingelheim (PBM, NS) and grant funding paid to the University of Glasgow for SGLT2 inhibition trials from Boehringer Ingelheim (PBM, NS) and AstraZeneca (NS). Unrelated to SGLT2 inhibition but related to chronic kidney disease and cardiometabolic diseases, PBM has consulted for Vifor, Pharmacosmos, GlaxoSmithKline, and Astellas; and NS has consulted for and or received lecture fees from Abbott Laboratories, Afimmune, Amgen, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Novartis, Novo Nordisk, Pfizer, and Sanofi, and received grant support paid to the University of Glasgow from Novartis and Roche Diagnostics.